No interaction was observed between subtype and treatment for the OS endpoint either (pinteraction = 0.33), with HR point estimates favoring tDD EC/D in luminal (HR = 0.86, 95% CI 0.64–1.16), HER2-positive (HR = 0.54, 95% CI 0.30–0.99), but less so in triple negative breast cancer patients (HR = 0.90, 95% CI 0.57–1.41). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.